FDA Shows Flexibility in Rare Disease Drug Development

Clinical Trials Advisor
A A
Companies developing drugs for rare diseases that lack alternative treatments may be able to start clinical trials without the standard toxicology studies, provided they justify the approach, the FDA says.

To View This Article:

Login

Subscribe To Clinical Trials Advisor